In vitro and in vivo model of ebv-positive activated diffuse large b cell lymphoma with plasmacytic differentiation by Nichele Ilaria
  
 
 
 
UNIVERSITA‟ DEGLI STUDI DI VERONA 
 
DIPARTIMENTO DI 
PATOLOGIA E DIAGNOSTICA 
 
SCUOLA DI DOTTORATO DI 
SCIENZE BIOMEDICHE TRASLAZIONALI 
 
 
DOTTORATO DI RICERCA IN 
PATOLOGIA ONCOLOGICA E FISIOPATOLOGIA RIGENERATIVA TISSUTALE 
UMANA 
 
CICLO /ANNO  XXIV/ 2009 
 
 
 
 
 
 
TITOLO DELLA TESI DI DOTTORATO 
 
”IN VITRO AND IN VIVO MODEL OF EBV-POSITIVE ACTIVATED 
DIFFUSE LARGE B CELL LYMPHOMA WITH PLASMACYTIC 
DIFFERENTIATION” 
 
S.S.D. MED/08 
 
 
 
 
 
 
 
Coordinatore:  Prof. ALDO SCARPA 
Tutor:  Dott. MAURO KRAMPERA 
 
 
 
PhD Student: Dott.ssa  ILARIA NICHELE 
 
 2 
     
 
 
 
TABLE OF CONTENTS 
RIASSUNTO ........................................................................................................................ 3 
ABSTRACT .......................................................................................................................... 5 
1 INTRODUCTION .......................................................................................................... 6 
1.1 Primitive diffuse large B cell lymphoma: general aspects .................................................. 6 
1.2 Biology and pathogenetic pathways in diffuse large B cell lymphoma ............................ 12 
1.3 Diffuse large B cell lymphoma derived from lymphoproliferative diseases .................... 16 
1.4 EBV infection and malignancies ...................................................................................... 19 
1.5 Human cell lines and animal models ................................................................................ 22 
2 AIMS ............................................................................................................................ 25 
3 METHODS ................................................................................................................... 26 
3.1 Cell collection and culture ................................................................................................ 26 
3.2 Immunophenotypic analysis ............................................................................................. 27 
3.3 Determination of DNA content ......................................................................................... 28 
3.4 DNA and RNA extraction, cDNA synthesis ..................................................................... 28 
3.5 Analysis of VH rearrangement, p53, CD79B and Card 11 mutation................................ 29 
3.6 Preparation of formalin-fixed paraffin-embedded (FFPE) cell block and 
immunohistochmemical staining ...................................................................................... 30 
3.7 Establishment of mouse in vivo model ............................................................................. 32 
3.8 EBV status evaluation ....................................................................................................... 33 
3.9 Karyotyping ...................................................................................................................... 33 
3.10 Fluorescence in situ hybridization (FISH) ........................................................................ 34 
4 RESULTS ..................................................................................................................... 35 
4.1 Establishment and characterization of VR09 cell line ...................................................... 35 
4.2 Immunophenotyping and immunohistochemistry ............................................................ 36 
4.3 Cell cycle .......................................................................................................................... 38 
4.4 IGVH, TP53, CARD11 and CD79B mutation analysis .................................................... 39 
4.5 Mouse Model .................................................................................................................... 39 
4.6 EBV status ........................................................................................................................ 42 
4.7 Karyotyping ...................................................................................................................... 42 
4.8 Fluorescence in situ hybridization (FISH) ........................................................................ 42 
5 DISCUSSION ............................................................................................................... 45 
 
 
  
 3 
RIASSUNTO 
 
Le malattie linfoproliferative croniche possono evolvere 
istologicamente in linfomi ad alto grado di malignità. E‟ noto come il 
virus di Epstein-Barr giochi un ruolo importante nella patogenesi di 
alcuni linfomi aggressivi e come sia associato alla trasformazione 
istologica di forme indolenti. E‟ nota inoltre la sua capacità 
trasformante di cellule in vitro. Le linee cellulari rappresentano un 
importante strumento di ricerca poiché facilitano lo studio della 
biologia di molte malattie e l‟applicazione di nuove terapie mirate. 
VR09 é una nuova linea cellulare di linfoma B diffuso a grandi cellule 
(DLBCL) con differenziazione plasmacitica realizzata nel nostro 
laboratorio e derivante da un caso di malattia linfoproliferativa B. 
Abbiamo dettagliatamente studiato la linea cellulare attraverso la 
caratterizzazione immunofenotipica, immunoistochimica, molecolare, 
citogenetica e mediante FISH. Abbiamo inoltre testato  il potenziale 
tumorigenico di VR09 in vivo. Le cellule in sospensione hanno 
mostrato capacità proliferativa in vitro dopo alcuni mesi e capacità di 
sviluppare una massa sottocutanea quando inoculate sottocute in topi 
immunodeficienti Rag2-/- γ-chain-/- . Sia le cellule in vitro che quelle 
derivate dalla massa sottocutanea hanno mostrato un profilo 
immunoistochimico corrispondente ad uno stadio “attivato” della 
maturazione B con aspetti di differenziazione plasmacitica (CD19+, 
CD20+, CD79a+, CD79b+/-, CD138+/-, cyclina D1-, Ki67 80%, IgM+, 
IgD+, MUM1+, MDNA+, CD10-, CD22+, CD23+, CD43+, K+, λ-, 
Bcl2+, Bcl6-) e la  presenza di EBV in forma episomica. E‟ stata inoltre 
identificata la trisomia del cromosoma 12, la presenza di ipermutazioni 
somatiche nella regione VH, la mutazione dei geni Card11 e CD79B, e 
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la presenza di p53 in forma wild-type. Questa nuova linea cellulare 
potrebbe essere utile per caratterizzare in modo più approfondito le 
forme di DLBCL con differenziazione plasmacitica e testare in esse 
nuove terapie mirate.  
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ABSTRACT 
 
Background: B-cell lymphoproliferative diseases can show plasmacytic 
differentiation and may potentially progress to diffuse large B cell 
lymphoma (DLBCL). Epstein-Barr virus infection may cause the 
transformation of malignant cells in vitro.  
Design and Method: we established VR09 cell line, a DLBCL cell line 
with plasmacytic differentiation, obtained from a case of atypical B-cell 
chronic lymphoproliferative disease with plasmacytic features. We used 
flow cytometry, immunohistochemistry, polymerase chain reaction, 
cytogenetic analysis and florescence in situ hybridization to 
characterize this cell line. We also assessed whether VR09 has 
tumorigenic potential in vivo. 
Results:  cells in suspension revealed plasmacytic features and grew as 
spherical tumors when inoculated subcutaneously into immunodeficient 
Rag2
-/- γ-chain-/- mice. VR09 cell line and tumors displayed the 
phenotype of activated stage of B cell maturation, with secretory 
differentiation (CD19+ CD20+ CD79a+ CD79b+/- CD138+/- cycline 
D1- Ki67 80% IgM+ IgD+ MUM1+ MDNA+ CD10- CD22+ CD23+ 
CD43+ K+, λ- Bcl2+ Bcl6-); in addition they displayed episomal EBV 
genome, chromosome 12 trisomy, absence of c-MYC rearrangement, 
presence of somatic hypermutation in the VH region, mutations of Card 
11 and CD79B genes, and wild-type p53.  
Conclusion: This new EBV-positive cell line may be useful to further 
characterize activated DLBCL with plasmacytic features. 
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1 INTRODUCTION 
1.1 Primitive diffuse large B cell lymphoma: general aspects 
 
Diffuse large B cell lymphoma (DLBCL) is the most common form of 
non-Hodgkin Lymphoma in the western countries with age-related 
increasing incidence, from 2 cases per 100,000 at 20-24 years of age to 
112 cases per 100,000 by 80-84 years (Yancik, 2004); however, 
DLBCL incidence is 1.5-fold higher in males and there are significant 
racial differences, with increase rate in Caucasians (Fisher RI, 2004). It 
is characterized by aggressive evolution, with a median survival of less 
than one year in untreated patients. 
On the whole, the incidence of non-Hodgkin lymphomas increased 
dramatically in the last three decades, thus making these diseases the 
seventh most common cancer type. Several factors have contributed to 
this increase, including more sensitive methods to make proper 
diagnosis, improvements in reporting of haematological malignancies, 
changes in the classification systems used for lymphoid malignancies 
and human immunodeficiency virus (HIV) infection that is associated 
with the increase in HIV-associated lymphomas (Friedberg, 2008).  
Although the etiology of DLBCL still remains unknown for the 
majority of patients, increased risk of lymphoma, including DLBCL, 
has been observed in association with viral infections, chemotherapy 
and conditions affecting immune system, such as autoimmune diseases, 
organ transplantation and primary or acquired immunodeficiencies. In 
particular, several infectious agents have been linked to the risk of 
lymphoma, such as Epstein-Barr virus (EBV), human herpes virus 8 
(HHV 8), Helicobacter pylori, Chlamydia psittaci and hepatitis C virus 
(HCV) (Fisher SG, 2004). 
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Clinical, morphological and molecular heterogeneity of DLBCL has 
been known for a long time. The attempts to define DLBCL subgroups 
simply on the basis of morphology have largely failed due to the wide 
diagnostic discrepancies among histologists. Thus, the classification of 
human lymphomas has evolved constantly during decades. Recently, 
DLBCL nomenclature in 2008 World Health Organization (WHO) 
classification of the lymphoid tissue tumors have been modified to 
include some newly defined entities on the basis on distinctive clinical, 
pathological or biological features (Table 1).  
 
CLASSIFICATION 
Diffuse Large B cell Lymphoma (DLBCL), not otherwise specified 
Diffuse Large B cell Lymphoma subtypes 
      T-cell/histiocyte rich large B cell lymphoma  
      Primary DLBCL of the CNS 
      Primary cutaneous DLBCL, leg type 
      EBV positive DLBCL of the elderly 
Other Lymphomas of large B cells 
      Primary mediastinal large B cell lymphoma 
      Intravascular large B cell lymphoma 
      DLBCL associated with chronic inflammation 
      Lymphomatoid granulomatosis 
      ALK positive large B cell lymphoma 
      Plasmablastic lymphoma 
      Large B-cell lymphoma arising in HHV8-associated multicentric Castleman disease 
      Primary effusion lymphoma 
 Borderline cases 
     B cell lymphoma, unclassifiable, with features intermediate between DLBCL and Burkitt 
lymphoma 
     B cell lymphoma, unclassifiable, with features intermediate between DLBCL and 
classical   Hodgkin‟s lymphoma 
Table 1. World Health Organization (WHO) Classification of DLBCL 
 
However, most DLBCL do not possess specific clinical or pathological 
features and, therefore, are included in the group of DLBCL not 
otherwise specified (NOS) (Campo, 2011). 
By the gene expression profiling technology (GEP) developed in the 
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last decades, DLBCL have been further classified into distinct 
molecular subgroups. The first subgroup have the gene expression 
profile clustering with that of normal germinal center B (GCB) cells 
and has been named „GCB variant‟. The second group has a set of 
signature genes similar to that of mitogenically activated blood B cells 
(ABC) and has been termed „ABC variant‟. These subsets are 
associated with specific genetic alterations, different molecular 
signalling pathways and different clinical outcome (Rosenwald, 2002) 
(Figure 1).  
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Figure 1. Subgroups of DLBCL according to gene expression profiling.  
A. Hierarchical clustering of DLBCL according  to the level of expression of 100 
genes. Red areas indicate increased expression, and green areas decreased 
expression. Each column represents a single DLBCL type and each row represents 
a single gene. B. Overall survival after chemotherapy among untreated patients 
according to gene expression subgroup. 
 
B 
A 
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Clinical presentation of DLBCL is usually characterized by rapidly 
enlarging lymph nodes. However, the main localization may be 
extranodal in up to 40% of patients, commonly involving skin, 
gastrointestinal tract, central nervous system, lungs, genitourinary tract 
or bones. Approximately 15% of patients may have bone marrow 
involvement, about one-third B symptoms (fever, night sweats and 
weight loss), nearly 50% Ann Arbor system stage III/IV disease and 
more than 50% elevated serum lactate dehydrogenase (LDH) levels 
(Flowers, 2010). However, DLBCL patients normally have highly 
variable clinical course and treatment responses. 
Although DLBCL is normally characterized by aggressive 
development, it is commonly curable with conventional anthracycline-
based chemotherapy. Advances in the management of DLBCL during 
the last decade, including the advent of monoclonal antibodies, have led 
to excellent outcome for many patients. It is now clear that rituximab-
containing regimens improve response rate and survival of DLBCL 
patients regardless of age. However, relapse remains a consistent 
clinical problem that needs a better understanding of disease biology to 
improve current strategies for salvage therapy based on targeted therapy 
approaches (Flowers, 2010). 
The efforts to predict DLBCL outcome led to propose in 1993 the 
International Prognostic Index (IPI), which remains nowadays the 
primary clinical tool used to predict outcome. IPI score is based on the 
consideration of 5 risk parameters, with one point given for each factor, 
i.e. stage III/IV disease, elevated LDH, age >60 years, Eastern 
Cooperative Oncology Group (ECOG) performance status and 
involvement of > 1 extranodal site. This way, IPI scoring system 
stratify patients into 4 risk groups with a 5-year overall survival (OS) 
ranging from 26% to 73% (Shipp, 1993).  
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However, outcome prediction has been recently improved by the 
addition of biological prognostic factors. As previous mentioned, 
DLBCL have been divided into two subgroups, GCB and ABC types, 
according to different gene expression profiles. GCB and ABC 
subtypes have different pathogenetic mechanisms that have impact on 
the development of target therapies. When treated with CHOP 
(Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) or 
CHOP-like chemoterapeutic regimens, patients with GCB DLBCL 
have a better survival independently from IPI score (Rosenwald, 2002). 
The prognostic value of GEP classification remains significant also for 
DLBCL patients treated with Rituximab plus CHOP or CHOP-like 
therapy (Lenz, 2003).  
As gene expression profiling technology has not easily tranferred into 
common practice, an immunohistochemical algorithm have been 
proposed and validated for classification of DLBCL into GCB and 
ABC subtypes. The initial immunohistochemical algorithm proposed 
by Hans et al. (Hans, Blood 2004) was improved by a consortium of 
hematopathologists, leading to a new algorithm with 93% concordance 
with gene expression profiling (Figure 2). Independently of IPI score, 
GCB and ABC subtypes, as defined by IHC, showed significant 
differences in event-free survival and overall survival among patients 
treated with and without Rituximab-based regimens. (Choi, 2009).  
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Choi, Clin Cancer Res 2009 
Figure 2. The new algorithm and the Hans‟ algorithm. 
 
1.2 Biology and pathogenetic pathways in diffuse large B cell 
lymphoma 
 
DLBCL grows diffusely, completely subverting the normal lymph node 
architecture. It expresses different pan-B markers, such as CD19, 
CD20, CD22 and CD79a, but may lack one or more of them. Surface 
and/or cytoplasmic immunoglobulins can be demonstrated in 50-70% 
of cases. Some cases express CD5 (10%) or CD10 (25-50%). CD5+ 
DLBCL do not express cyclin D1, thus differing from blastoid variants 
of mantle cell lymphoma. BCL2 is expressed in approximately 30-50% 
of cases and nuclear BCL6 expression is observed in a very high 
proportion of cases. Expression of plasma cell-associated markers, such 
as CD138, is rare. The proliferative fraction as detected by Ki-67 
staining is usually high and may be greater than 90% in some cases 
(Gatter, 2001).   
Peripheral B cells of either germinal or post-germinal centre are 
supposed to be the cells of origin of DLBCL, thus suggesting that this 
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tumor can derive from two different maturation stages of B cell 
development. As previously mentioned, this distinction reflects the two 
major molecular categories that have been recognized over the past 
decades according to gene expression profiling studies, i.e. GCB and 
ABC subtypes (Alizadeth, 2000). 
 
Germinal Center (GC) 
In the physiologic development of B cells, GC is the hallmark of T cell-
dependent immune responses. Once naïve B cells encounter their 
antigen, a rapid and intense cell proliferation occurs, leading to the 
formation of histologically well-defined structures (MacLennan, 1994). 
Within the GC, the immunoglobulin genes of the B cells are modified 
through the process of somatic hypermutation and class switch 
recombination, two events aimed at favouring the emergence of cells 
producing antibodies with increasing antigen affinity and capable of 
distinct effector functions. GC can be divided into two anatomically 
distinct areas: the dark zone, populated by rapidly dividing centroblasts, 
and the light zone, which is composed of smaller non-dividing 
centrocytes in close contact with follicular dendritic cells (Klein, 2003). 
Centroblasts are characterized by elevated expression of BCL6, a 
powerful transcriptional repressor that modulates the expression of a set 
of genes, including those involved in B cell receptor (BCR) and CD40 
signalling, T cell-mediated B cell activation, induction of apoptosis, 
response to DNA damage, negative regulation of cell cycle progression, 
several cytokines pathways and plasma cell differentiation. This 
complex transcriptional program driven by BCL-6 plays a critical role 
in the GC and in DLBCL is frequently targeted by genetic lesions 
(Pasqualucci, 2011). When centroblasts stop proliferating, they 
differentiate into centrocytes that are rechallenged in light zone by the 
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antigen. Centrocytes expressing BCR either with reduced affinity for 
the antigen or self-reactive undergo apoptosis, while a few cells with 
high affinity antigen receptors are selected to differentiate into plasma 
cells or memory B cells (Klein, 2008). 
A key concept for the understanding of DLBC pathogenesis is the 
relationship between these tumors and the events that take place in 
normal B cell counterpart. GCB-DLBCLs appear to derive from 
proliferating CB, as their expression profile includes genes that are 
specific for GC B cells, such as BCL-6 (Alizadeth, 2000). Genetic 
lesions that are specific for GCB-DLBCL include: 1. t(14,18) 
translocation, which deregulates the expression of the anti-apoptotic 
BCL2 protein in 35-45% of cases, thus becoming insensitive to BCL-6-
mediated transcriptional repression (Ci, 2009); 2. MYC oncogene 
involvement altering cell proliferation and growth; 3. somatic 
heterozygous mutations in histone methyltransferases; 4. alterations 
inactivating acetyltransferase genes that impair the ability of this 
enzyme to acetylate known substrates, such as BCL-6 and p53, leading 
to constitutive activation of the oncoprotein and decreased p53 tumor 
suppressor function; 5. somatic mutations affecting BCL6 self control 
circuits, thereby causing its deregulated expression. Other lesions 
consist in mutations and deletions of the p53 tumor suppressor gene, 
often detected in cases deriving from the transformation of low grade 
lymphoma and associated with chromosomal traslocation of BCL2 and 
deletions of the tumor suppressor PTEN (Pasqualucci, 2011).  
 
Activated B Cell (ABC) 
Plasma cells represent the final step of B cell differentiation as cell 
mediators of humoral immunity. After antigen exposure, naïve B cells 
can differentiate rapidly into short-living plasma cells secreting 
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unmutated immunoglobulin within the medullary zone of lymph nodes 
and splenic red pulp. In case of antigen persistence, B cells expressing 
high-affinity Ig are selected within GC and give rise to early plasma 
cells. Some plasma cell precursors can migrate to the bone marrow or 
to the lamina propria of mucosae, where they differentiate into long-
living plasma cells. Whereas terminally differentiated plasma cells do 
not divide, maturing plasma cell precursors, i.e. plasmablasts, undergo 
cell division (Tarte, 2003). In humans, three subsets of normal plasma 
cells have been isolated, representing a gradient in plasma cells 
maturation: early plasma cells in tonsils, transitional plasma cells in 
peripheral blood and mature plasma cells in bone marrow (Medina, 
2002). In particular, peripheral blood B cells differentiating into 
polyclonal plasmablastic cells are highly proliferative, produce large 
amount of Ig, have the morphologic and phenotypic features of plasma 
cells and express high levels of plasma cells specific transcription 
factors, such as XPP-1, PRDI-BF1 and IRF-4 (Tarte, 2003).  
The ABC-DLBCL subgroup displays a transcriptional signature related 
to either plasmablastic B cells presumably blocked during plasma cell 
differentiation or mitogenically activated peripheral blood B cells. 
Their gene expression profile suggests that the putative cell of origin 
has received signals determining the downregulation of the GC specific 
program and the upregulation of genes required for terminal B cell 
differentiation, such as IRF 4 or XBP1. Thus, ABC DLBCL arises from 
post-germinal center B cells that stopped their plasmacytic 
differentiation (Alizadeh, 2000). 
Several genetic abnormalities are observed almost exclusively in ABC-
DLBCL, such as: 1. amplification of the BCL2 locus with the 
consequent inhibition of apoptosis; 2. mutations within NF-kB, BCR 
and JAK-STAT signalling pathways; 3. inactivating mutations and 
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deletions of PRDM1 tumor suppressor gene; 4. deletion or lack of 
expression of the CDkN2A tumor suppressor gene (Pasqualucci, 2011).  
In particular, a characteristic feature of ABC DLBCL is the constitutive 
activation of the NF-kB pathway, which plays a pivotal role in 
proliferation, differentiation and survival of normal lymphoid cells 
(Davis, 2001). This abnormality has been linked to malfunctioning of a 
variety of upstream proteins including CARD11. In normal B cells, 
CARD11 is engaged during antigenic stimulation of BCR signalling 
and acts as signalling scaffold protein to coordinate the activation of 
IkB kinase beta, a positive regulator of the NF-kB pathway. About 10% 
of ABC DLBCLs have mutant CARD11 isoforms that activate NF-kB. 
Missense mutations have been detected, all whitin exons encoding the 
coiled-coil domain (Lenz, 2008). For the majority of ABC DLBCL 
cases, NF-kB activation can be observed in absence of CARD11 
mutations. In these cases, NF-kB activation may be linked to 
persistently active BCR signalling. Somatic mutation affecting the 
immunoreceptor tyrosine-based activation motif (ITAM) of CD79B 
and CD79A was detected frequently in ABC DLBCLs, but rarely in 
other lymphomas. These mutations increase surface BCR expression 
and modulate Lyn kinase, a feedback inhibitor of BCR signalling 
(Davis, 2010).  
 
1.3 Diffuse large B cell lymphoma derived from 
lymphoproliferative diseases 
 
Chronic B cell lymphoproliferative disorders are a biologically 
heterogeneous group of malignant diseases characterized by 
accumulation of mature B cells in bone marrow, peripheral blood and 
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lymphoid tissues (Pangalis, 1999).  They are often diagnosed by flow 
cytometric immunophenotyping that identifies a clonal light chain-
restricted population expressing B cell markers in the blood or bone 
marrow (Dronca R, 2010) (Table 2). 
 
CONDITION SmIg CD5 CD43 CD22 CD23 CD25 FMC7 CD103 CD11C CD10 
CYTOGENETIC 
ABNORMALITIES 
AND 
MOLECULAR 
CHARACTERISTICS 
CLL -/+ + + -/+ + +/- -/+ - -/+ - +12, de13q14, 6q-, 
11q+, 14q+ 
Lymphoplasmacytoid 
lymphoma or 
immunocytoma 
++ -/+ +/- + - -/+ + - -/+ - (CIg+, 100%), +12, 
13q-, 14q+,11q+ 
Prolymphocytic 
leukemia 
++ -/+ + + -/+ - + - - -/+ t(11;14) (q13;q32), 
bcl-1 
Hairy-cell leukemia ++ - + + - + + + + - HC2+,+5 
Splenic lymphoma 
with villous 
lymphocytes 
++ -/+ + + +/- -/+ + -/+ +/- -/+ 
t(11;14) (q13;q32), 
del/t  
7q22-35,  2p11 
Marginal-zone B-cell 
lymphoma 
++ - -/+ +/- +/- - + - +/- - (CIg+, 40%), +3, 
t(11;18) 
Mantle-cell 
lymphoma 
++ + + +/- - - +/- - - -/+ t(11;14) (q13;q32), 
bcl-1 
Follicular lymphoma ++ -/+ - +/- -/+ - + - - +/- t(14;18) (q32;q21), 
bcl-2 
Rozman, N Engl J Med 1995 
Table 2. Immunophenotypic, cytogenetic and molecular features of malignant conditions 
affecting mature B cells. 
 
However, in a minority of patients, no specific pathological diagnosis 
can be done. Indeed, some entities may have overlapping features, 
frequently presenting diagnostic problems and leading to the simple 
definition of atypical lymphoproliferative disease (Rozman, 1995). 
Moreover, several types of small B cell neoplasms can display 
plasmacytic differentiation without specific markers of 
lymphoplasmacytic lymphoma. Thus, sometimes only a partial 
diagnosis of small B cell lymphoma with plasmacytic differentiation 
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can be done (Campo, Blood 2011).  
Histologic transformation from indolent to more aggressive lymphoma 
is a common feature of virtually all histologic subtypes of chronic B 
cell lymphoproliferative disorders. Sometimes, the morphologic 
characterization of DLBCL subtypes can be complicated by the 
presence at diagnosis of small B cell components. In most cases, this 
presentation occurs in patients with history of indolent lymphoma, thus 
permitting the diagnosis of histologic transformation. However, a 
proportion of DLBCL are unknown indolent lymphomas diagnosed 
only at the time of their transformation (Ghesquieres, 2006). 
Histologic transformation of follicular cell lymphoma is the most 
frequently described and studied entity (Yuen, 1995). However, 
histologic transformation can occur in other low grade B cell 
lymphoproliferative diseases, such as marginal zone lymphoma 
(Dungarwalla, 2008), MALT lymphoma (Liu, 2010) 
lymphoplasmacytic lymphoma / Waldenstrom macroglobulinemia 
(Shiseki, 2011) and small lymphocytic lymphoma/B cell chronic 
lymphocytic leukemia (Rossi, 2009).  
The accumulation of additional genetic abnormalities are responsible 
for histologic transformation of indolent lymphomas to diffuse 
aggressive histotypes, mainly in clonally-related histologic 
transformation that happens in most cases of DLBCL evolving from 
follicular lymphoma, marginal zone lymphoma and lymphoplasmacytic 
lymphoma (Freedman, 2005) and in about 80% of cases of DLBCL 
evolving from chronic lymphocytic leukemia (Richter syndrome) 
(Rossi, 2009).  The specific genetic lesions identified include 
alterations in proliferation-regulating genes (C-MYC), cell cycle 
regulators (CDKN2a, CDKNb), and programmed cell death inducers 
(TP53, C-MYC, BCL2). Moreover, acquisition of 17p13 deletion is a 
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frequent molecular event in Richter syndrome and in other types of 
transformation from indolent to aggressive B cell malignancies (Rossi, 
2008). However, chromosomal aberrations usually found in the related 
indolent lymphomas have been detected also in DLBCL, such as 
t(14;18) in cases originated from follicular lymphoma, aberration of 
chromosomes 3, 18 and 7 in cases derived from marginal zone 
lymphoma, and deletions of 11q, 13q, 6q or trisomy 12 in cases derived 
from chronic lymphocytic leukemia (Ghesquieres, 2006). 
The pathogenetic mechanisms of not clonally-related histologic 
transformation cannot be directly ascribed to the accumulation of 
genetic lesions in the low-grade clone, but rather to alterations of the 
host genetic background and immunologic functions, or 
microenvironment dysfunctions enhancing the probability of DLBCL 
to develop (Rossi, 2009). 
DLBCL developing in a patient with previous indolent lymphoma is 
usually resistant to chemotherapy and the prognosis is poorer than in de 
novo DLBCL. Median overall survival ranges from 2.5 to 22 months, 
although is generally shorter than one year (Bastion, 1997).  
 
1.4 EBV infection and malignancies 
 
Epstein-Barr virus is a gamma-herpesvirus with 172-kb DNA genome, 
which infects more than 90% of world population. It has a tropism for 
epithelial cells (e.g oral and nasopharyngeal mucosa), lymphocytes (B 
and T cells) and myocytes, but it predominantly infects, replicates and 
persists in B cells (Thorley-Lawson, 2001). Primary infection of EBV 
may cause short-term proliferation of B cells in human hosts. The 
infection is usually self-limited and controlled by the strongly elevated 
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T cell immune response (Chen, 2011). Then, EBV persists latently in 
the host inside long-life memory B cells. These cells can undergo 
limited expansion or extrafollicular proliferation and persist in the host 
for a long time. EBV can reactivate periodically and infect new hosts 
through saliva. Thus, like other herpesvirus, it has both a latent phase of 
infection and a lytic (productive) phase that produces new infectious 
virions (Michelow, 2012). If the infection occurs in adolescence or 
adulthood, it may cause the clinical symptoms of infectious 
mononucleosis, with up to 50% of T cells in the host specific to the 
virus; however, most EBV infections are initially asyntomatic (Chen, 
2011). In vivo and in vitro EBV latent state is characterized by the 
absence of viremia and maintenance of the viral genome into the cell 
nucleus, where persists as extrachromosomal circular molecule named 
episome (Tsimberidou, 2005).  
During latency, a limited number of EBV-encoded proteins and several 
non-coding RNAs are expressed. These include two EBV encoded 
small RNAs (EBER1 and EBER2), nuclear antigens and membrane 
proteins (Chen, 2011). In the latent form, EBV-encoded genes ensure 
the survival of the viral genome, allowing it to circumvent host‟s 
immune surveillance by limited expression of viral proteins. 
Genetic and biochemical experiments demonstrated that several viral 
proteins directly contribute not only to latency of infected cells in vitro 
and in vivo, but also to growth transformation (Michelow, 2012). 
In vitro, EBV infects resting human B lymphocytes and transforms 
them into clonal lymphoblastoid cells, a hallmark process termed 
growth transformation. After infection, B cells become activated as a 
result of the expression of EBV latent antigens and may proliferate 
indefinitely (Kelly, 2006). Nuclear antigens, such as EBNA 1, -2, -3A, 
3B, 3C, -LP, and membrane proteins including LMP1, PMP2A and -B 
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are required for this transformation process and the coding genes are 
consistently expressed in lymphoblastoid cells. Typically, EBV latent 
genes mimic cellular functions; for instance, LMP1 indirectly inhibits 
apoptosis by upregulating several cellular antiapoptotic genes 
presumably through the induction of the NF-kB pahway, thus 
promoting cell proliferation and targeting physiological signalling 
pathways (Altmann, 2005).  
Transforming capacity of EBV suggests its oncogenic role. Indeed, 
EBV is highly associated with several neoplastic diseases, such as 
endemic Burkitt Lymphoma, T cell lymphoma, nasopharyngeal 
carcinoma, Hodgkin Lymphoma and immunoblastic lymphoma in 
immunocompromised patients (Young, 2004).  
EBV has been also detected in low-grade lymphoproliferative diseases, 
such as B-cell chronic lymphocytic leukemia  (CLL), where it has been 
shown to correlate in some cases with disease transformation into 
Richter syndrome (Jeffrey 2010, Rossi 2009, Ansell 1999). The 
importance of EBV in the pathogenesis of lymphoma emerges also in 
the last update of WHO classification of lymphoid neoplasms, which 
recognizes several DLBCL entities characterized by EBV infection of 
tumor cells, including EBV positive-DLBCL of the elderly that are still 
considered a provisional entity requiring a more precise definition 
(Campo, 2011).  
The mechanisms by which EBV infection causes lymphomagenesis are 
complex. In many malignancies EBV presence in episomal form within 
tumor cells indicates that the virus entered these cells prior to their 
clonal expansion. In the immunocompetent host, latent EBV infection 
is under control of the immune system and the vast majority of the 
individuals never develops EBV-associated tumors. Neverthelss, viral 
genome, once integrated inside B cell DNA without killing the cells, 
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may both affect the control pathways of cell growth, thus favouring 
clonal B cell expansion, and prevent them from being destroyed by the 
immune system (Thompson, 2004). A percentage of EBV-infected 
patients with lymphoma express LMP and EBNA2 viral antigens, 
which are well known transforming factors for B cells. However, 
patients with Burkitt lymphoma fail to express these proteins, thus 
suggesting distinct roles of viral genes in transformation process 
(Hamilton-Dutoit, 1992). Additional factors may play a role in the 
development of EBV-associated neoplasms, including genetic 
susceptibility, environmental factors such as parasitic infections, 
nutritional issues and pathological conditions affecting host immune 
status (Michelow, 2012). 
EBV identification in neoplastic cells can be very helpful for diagnosis 
and can be obtained through different methods, including commercial 
antibodies against EBNAs (detected by immunofluorescence) and 
LMP-1 (detected by membrane and cytoplasmic immunohistochemical 
staining), RNA in situ hybrization to detect EBERs and/or polymerase 
chain reaction (PCR) (Gulley, 2002).  
In situ hybridization for EBER is perhaps the best test to detect and 
localize latent EBV in tissue and cell samples (Cohen, 2000).  
 
1.5 Human cell lines and animal models  
 
Human lymphoma cell lines and animal models have contributed 
significantly to better understand the physiopathology of hematopoietic 
tumors. However, the number of established cell lines from ex vivo 
tumor cells is quite low due to the difficulty in reproducing in vitro the 
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microenviromental conditions supporting in vivo cell growth (Drexler, 
2000).  
EBV-associated lymphoblastoid cell lines have been the first to be 
achieved; their phenotype corresponds to activated B cells with non-
malignant properties, as they are polyclonal, diploid and do not form 
tumors after subcutaneous inoculation in nude mice (Nilsson, 1992). In 
addition, several hematopoietic cell lines of malignant origin, including 
lymphoma, myeloma and leukemia cell lines, have been established and 
studied; some of them are EBV-positive (Nilsson, 1975). Malignant 
cell lines are generally characterized by monoclonal origin, aneuploidy, 
genetic alterations, differentiation arrest, sustained proliferation in vitro 
and capability of maintaining most cellular features and specific genetic 
alterations of the primitive tumor; nevertheless, primitive malignant 
cells may often change some morphological and phenotypic features 
once cultured in vitro, especially if EBV-positive. Leukemia-lymphoma 
cell lines are genetically unstable at both cytogenetical and molecular 
levels; they may acquire additional numerical and structural 
chromosome alterations and various types of point mutations along in 
vitro expansion, thus becoming more and more different from primary 
ex vivo tumor cells (Drexler, Leuk Res 2000). 
The first malignant hematopoietic cell line was obtained from a 
Burkitt‟s lymphoma patient in 1963. Since then a large number of cell 
lines has been obtained, although not all of them have been thoroughly 
characterized. Cell lines have been recently described for multiple 
myeloma, Waldenstrom‟s macroglobulinemia (Hodge, 2011), mantle 
cell lymphoma (Zamò, 2006), chronic myeloid leukemia (Park, 2010) 
and acute lymphoblastic leukemia (Okabe, 2010); by contrast, cell lines 
from lymphoproliferative diseases were obtained only if infected by 
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EBV or derived from CLL in prolymphocytoid transformation 
(Stacchini, 1999).  
Cell lines have been used also in vivo as xenografts into 
immunodeficient animals to study the different phases of tumor 
development and the role of host immune system. Severe combined 
immune deficient (SCID) mice, lacking mature T and B cells (but still 
showing NK cell activity), have been employed as in vivo model for 
multiple myeloma (Ashmann, 1995) or CLL (Mohammad, 1996).  
Recently, genetically-modified immunodeficient mice have been 
transplanted with human-derived hematopoietic stem cells (‘humanized 
mice’). This model is becoming a powerful tool to investigate human 
diseases, as it recapitules entirely human tumor development, without 
any interference by host immune system. Several immunodeficient 
mice have been developed: NOD/Scid mice exhibit deficiencies in 
macrophage, dendritic cell, T, B and NK cell and complement 
functions. Rag2-/- γ-chain-/- mice are also commonly used to establish 
humanized mice, as their genetic background is associated to high 
efficiency of human cell engraftment (Ono, 2011). 
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CHAPTER 2 
 
2 AIMS 
 
When considering the treatment of malignant diseases, both in clinical 
and research setting, it is crucial to understand their pathobiological 
features. The availability of stable human leukemia-lymphoma cell 
lines and animal models have contributed significantly to this aim, thus 
representing an important tool for therapeutic advances.  
Biological features of DLBCL have been recently included in the last 
WHO classification and they are used to differentiate the treatment. 
However, some DLBCL subtypes have not been completely studied yet 
and sometimes their diagnosis is still problematic because of the lack of 
extensive analysis, i.e. DLBCLs displaying phenotype that resembles 
late stage of B cell differentiation.  
We have established a new cell line, called VR09, which is an EBV-
positive DLBCL with activated phenotype and plasmacytic 
differentiation, derived from a patient with low-grade 
lymphoproliferative disease. Aims of this study were:  
1. to characterize VR09 cell line by means of different approaches, such 
as immunophenotyping, immunohistochemistry, PCR, cytogenetic 
analysis and fluorescence in situ hybridation (FISH);   
2. to test VR09 tumorigenic potential in vivo into Rag2-/- γ-chain-/- 
mice through primary and secondary transplants;  
3. to provide a new model of DLBCL with plasmacytic differentiation 
for further studies in vitro and in vivo. 
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3 METHODS 
3.1 Cell collection and culture 
 
A 75-year old Caucasian man was admitted to hospital in September 
2008 for fever, neutropenia and lymphocytosis (WBC 20.1x10
9
/L, with 
neutrophils 0.8x10
9
/L and lymphocytes 18.2x10
9
/L), and moderate 
anemia and trombocytopenia (Hb 9 g/dl, PLTS 93x10
9
/L). No 
significant superficial lymphoadenopathy or splenomegaly were found. 
A bone marrow sample was sent to our laboratory for first level-
immunophenotyping by flow cytometry (FACSCanto, Becton 
Dickinson Biosciences, CA, USA). Bone marrow smear appeared 
infiltrated (60%) by a cell population of lymphoplasmocytoid elements 
of small-medium size. First level-immunophenotyping showed the 
presence of a cell population expressing CD19, CD20, CD22, CD138, 
surface immunoglobulins (sIg) at high level, and negative for CD5, 
CD10, ZAP-70, thus suggesting the diagnosis of atypical B-cell chronic 
lymphoproliferative disease with plasmacytic features. No other exams 
could be performed, as the patient died of sepsis the following day. 
 
Mononuclear cells were purified from bone marrow sample by Ficoll-
Hypaque centrifugation (Lymphoprep, Fresenius Kabi Norge AS for 
Axis-Shield Poc AS, Oslo, Norway), washed in phosphate-buffered 
saline solution (PBS) and resuspended at 1x10
6
/mL concentration in 
RPMI 1640 + GlutaMAX 1X containing 10% heat-inactivated fetal 
bovine serum and 1% penicillin/streptomycin (all from GIBCO, 
Invitrogen). Cells were cultured in 75 cm
2
 flask and incubated in 
humidified 5% CO2 atmosphere at 37°C.  Half of culture medium was 
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replaced every 3-4 days maintaining the same cell density of 1x10
6
 
cells/mL.  
To determine growth kinetics, cells were seeded at lower density 
(350,000/mL) and counted at 0, 24, 48 and 72 hours by flow-cytometry 
(FACSCanto, Becton Dickinson, Italy). No mitogens or growth factors 
were added during culture. Cells were maintained in culture up to one 
year. Aliquots of cells were periodically frozen in culture medium 
supplemented with 10% dimethyl-sulfoxide (DMSO) and stored in 
liquid nitrogen.  
Cell morphology was evaluated on cytospins stained with May-
Grunwald Giemsa dye. 
 
3.2 Immunophenotypic analysis 
 
Cell vitality was assessed by acridine-orange/ethidium bromide staining 
and epifluorescent microscopy. Aliquots of 3x10
5
 cells were incubated 
for 15 minutes at room temperature with three-color combinations of 
appropriate monoclonal antibodies anti-human CD3, CD19, CD20, 
CD22, CD23, CD25, CD38, CD43, CD45, FMC-7, CD79b 7AAD 
(Becton Dickinson, Italy), CD5, CD10, K, λ, IgG, IgM, IgD (Dako, 
Italy), CD103 (Beckman Coulter, Italy), CD138 (Cytognos, Italy), and 
isotype controls (Becton Dickinson, Italy). Samples were analyzed by 
FacsCANTO flow cytometer with BD FACSDiva software. Data 
analysis was carried out using the laboratory‟s template for CLL; 
lymphocytes were identified by a gate made on their CD45 expression 
and morphologic parameters (side and forward scatters, SSC and FSC). 
The expression of antigens examined was assessed relatively to their 
respective isotypes controls.  
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3.3 Determination of DNA content 
 
DNA staining solution including 5 ml of hypotonic solution, 50 µg of 
propidium iodide (Bender MedSystems) and 20 µg of RNAse was 
prepared. An aliquot of the cells suspension was centrifuged and 
resuspended in PBS 100 µl; then, 1.5 x 10
5
 cells were incubated with 1 
ml of staining solution for two hours at 4°C. Samples were analyzed by 
FacsCANTO flow cytometer and analyzed by FacsCANTO flow 
cytometer with BD FACSDiva software. 
 
3.4 DNA and RNA extraction, cDNA synthesis 
 
DNA and RNA were obtained from 10
7
 cells by AllPrep 
DNA/RNA/Protein Mini Kit (Quiagen, Hilden, Germany). DNA 
quality was verified by spectrophotometry and RNA quality by the 
Agilent Bionanalyzer 2100; 1 µg of total RNA was reverse-transcribed 
by using SuperScript III First-Strand Synthesis System (Invitrogen, 
Carlsbad, California) and cDNA was used as a template for RT-PCR 
amplification using listed in Table 3. 
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Primers Sequence Ta° Amplicon lenght 
P53-1-F AAGTCTAGAGCCACCGTCCA 55°C 771 bp 
P53-1-R AAGTGTTTCTGTCATCCAAATACTC   
P53-2-F AGCCAAGTCTGTGACTTGCA 55°C 851 bp 
P53-2-R GGGGAACAAGAAGTGGAGAA   
Card11-1-F AGATGCAACGGGAGCCTGGC 55°C 631 pb 
Card11-1-R AGGTTAGCAGCTCCACGCGC   
Card11-2-F GGCCAAGGACCTGCAACGCT 55°C 703 pb 
Card11-2-R CCGCTCCACCTCCTCCAGCT   
Card11-3-F GAGGCCCTGGAGGACAGGCA 55°C 690 pb 
Card11-3-R TCCGCAGGAGCTAGGGCTGG   
Card11-4-F TCCTGCCCTACCATCCGCCC 55°C 671 pb 
Card11-4-R CAGCAGCTGGTGGCCCTCAC   
Card11-5-F TCCCAGCTCACCCTGCTGGG 55°C 739 pb 
Card11-5-R CCGAGATGATGCGGACCCGC   
Card11-6-F CCCGTCTCTCGCGAGCAAGC 55°C 928 pb 
Card11-6-R CGTCTGCTGGGGCAGCTCTG   
CD79B-1-F GCCTCGGACGTTGTCACGGG 55°C 858 pb * 
CD79B-1-R TGGGCCAGCTTCAGAGGCCA   
* Isoform 1: 858 pb; Isoform 2: 546 pb; Isoform 3: 861 pb 
Table 3. Primers used to amplify and sequence P53, Card 11 and CD79B genes 
 
3.5 Analysis of VH rearrangement, p53, CD79B and Card 11 
mutation  
 
Rearranged VH genes were analyzed as previously described (Zamò, 
2006), while TP53, CD79B and CARD11 genes were amplified and 
sequenced by using the primers reported in Table 3. VH and CD79B 
PCR bands were excised from agarose gels and purified by using spin 
columns (PureLink Quick Gel Extraction and PCR Purification Combo 
Kit, Invitrogen). PCR products were sequenced by dye terminator 
reaction (Big Dye Terminator Cycle Sequencing Kit v.3.1, Applied 
Biosystems, Warrington, UK) on AB3130XL automated sequencer 
(Applied Biosystems). P53 and CARD11 PCR products were directly 
purified with magnetic beads (Agencourt AMPure XP, Beckman 
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Coulter Genomics, Beverly, Massachussets, USA) and sequenced as 
reported above and by outsourcing to Base Clear BV (Leiden, The 
Netherlands).  
VH genes sequences were compared to published germline sequences 
using IgBLAST (http://www.ncbi.nlm.nih.gov/igblast/). Sequences with 
2% or less deviation from any germline IgVH sequence were 
considered unmutated. TP53, CD79B and CARD11 amplified 
sequences were compared to reported sequences by using Geneious 
software (Biomatters Ltd., Auckland, New Zeland). 
 
3.6 Preparation of formalin-fixed paraffin-embedded (FFPE) 
cell block and immunohistochmemical staining 
 
Briefly, 12x10
6
 cells were centrifuged, washed once in PBS and then 
incubated for 15 minutes in 4% buffered formalin. Cells were 
centrifuged again and resuspended in 1 ml of 1% low melting point 
agarose at 37°C; then, they were poured into disposable plastic moulds 
and cooled for ten minutes at +4° C. Solid agarose blocks were put 
inside a histological cassette, with 4% buffered formalin at room 
-thick 
sections were cut from the block and stained with ematoxilin-eosin to 
verify the quality of the cell inclusion. Many sections from the block 
were immunolabeled with the broad panel of antibodies described in 
Table 4. All samples were processed by using a sensitive 'Bond 
polymer Refine' detection system in automated Bond immunostainer 
(BondMax, Vision-Biosystem, Menarini, Florence, Italy). 
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Antibody Species Clone Source Diluition VR09 cell line Tumor masses 
Annexin a1 mouse B01P Abnova 100 neg neg 
Bcl-2 mouse 124 Dako 40 pos pos 
Bcl-6 mouse LN22 Novocastra 20 neg neg 
Cyclin D1 rabbit SP4 Neomarkers 10 neg neg 
CD03 rabbit SP7 Labvision 150 neg neg 
CD05 mouse 4C7 Novocastra 200 neg neg 
CD10 mouse 56C6 Novocastra 50 neg neg 
CD19 mouse LE-CD19 Serotec 200 pos pos 
CD20 mouse L26 Novocastra 100 pos pos 
CD22 mouse FPC1 Novocastra 20 pos pos 
CD23 mouse 1B12 Novocastra 100 pos pos 
CD25 IL2R mouse 4C9 Novocastra 100 pos/neg pos/neg 
CD38 mouse 38C03 Neomarkers 50 neg pos 
CD43 (T cell) mouse MT1 Novocastra 30 pos pos 
CD79alfa mouse JCB117 Dako 100 pos pos 
CD79beta mouse JS01 Novocastra 50 pos/neg pos/neg 
CD123 mouse 7G3 Bd 100 neg pos/neg 
CD138 
(syndecan-1) 
mouse BB4 Serotec 50 pos/neg pos/neg 
DBA44 hairy cell mouse DBA.44 Dako 20 neg neg 
FOXP1 mouse JC12 Abcam  500 neg pos/neg 
EBV (EBER)  
mRNA 
probe * 
Vision 
Byosistems 
 pos pos 
GCET1 mouse RAM341 Abcam  500 neg neg 
HHV-8 mouse 13B10 Novocastra 50 neg neg 
IgD rabbit polyclonal Dako 20 pos pos/neg 
IgG rabbit polyclonal Dako 10000 neg neg 
IgM rabbit polyclonal Dako 5000 pos/neg pos/neg 
Ki-67 mouse MM1 Novocastra 
20000 
(15‟ incubation) 
pos 
(40%) 
pos (80%) 
ZAP-70 mouse 2F3.2 Upstate 200 neg neg 
κ chains rabbit polyclonal Dako 50 pos pos 
λ chains rabbit  Dako 30000 neg neg 
MNDA mouse 235 
provided by 
CNIO ** 
2 pos pos 
MUM1 Protein mouse MUM1p Dako 50 pos pos 
PAX 5 mouse 1EW Novocastra 50 pos/neg pos/neg 
P53 Protein mouse DO-7 Novocastra 20 pos/neg pos/neg 
Sox11 rabbit polyclonal Atlas Sigma 50 pos/neg pos/neg 
TCL1A mouse 1-21 Santa Cruz 100 pos/neg pos/neg 
TdT rabbit polyclonal Dako 30 neg neg 
TRAcP mouse 26E5 Neomarkers 30 neg neg 
* see Materials and Methods    ** Reference 20 
Table 4. Marker expression by VR09 cell line and tumor masses, as assessed by 
immunohistochemistry performed on FFPE cell block. 
  
 32 
3.7 Establishment of mouse in vivo model 
 
Three month-old immunodeficient Rag2
-/- γ-chain-/- mice (Taconic 
animal models, New York‟s River Valley, NY USA) were injected 
either subcutaneously (s.c.) (n=6) with 5x10
6 
VR09 cells, resuspended 
in 0.2 ml PBS, or intravenously (i.v) (n=6) with 0.5 x 10
6 
VR09 cells 
resuspended in 0.1 ml PBS. Animals were checked three times a week 
for the development of tumors. When s.c. tumors developed up to 
approximately 2 cm of diameter, corresponding to a spheric volume of 
approximately 4.187 cm
3
, mice were sacrified. Half of the tumor mass 
was frozen and half included in paraffin according to standard 
procedures. Sections of 5-8 µm from each tumoral mass were prepared 
and analyzed for morphology, immunohistochemistry and FISH. 
Paraffin sections for immunohistochemistry were stained with a panel 
of antibodies, as described above (Table 4). Moreover, a little portion 
of the mass from two of six s.c injected mice, was dissected and 
mechanically dissociated into single-cell suspension; 1.5x10
6 
cells from 
each tumor were cultured in RPMI + 10% FBS and incubated as 
described above. Immunophenotipic analysis was performed on 
secondary cell culture after two months of culture, as previously 
described.  
Three of six mice injected i.v. were euthanized at +30 days, while the 
others were sacrificed after four months from the treatment. Spleen, 
liver, femurs, lymph nodes, lungs and bowel of the i.v. injected animals 
were collected and included in paraffine. Tissue sections were 
immunostained with antibodies against CD20 and CD138 to verify the 
presence on tumor infiltration. In addition, immunophenotyping with 
anti-human CD19 and CD45 monoclonal antibodies and isotype 
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controls was performed by standard procedures on peripheral blood 
mononuclear cells of all mice injected both s.c. and i.v.  
The in vivo studies were approved by Verona University Ethical 
Committee for experimentation on animals (Prot. n°51 del 16/06/11, 
D.lgs 116/92). 
 
3.8 EBV status evaluation 
The presence of EBV was assessed on both cells cultured in vitro and 
cells obtained from the tumoral mass developing after in vivo injection 
of VR09 cell line. Epstein-Barr virus-encoded RNA (EBER) 
hybridization was performed on cytoinclusion by means of specific 
fluorescein-conjugated EBER probes (Bond ISH EBER Probe, Vision-
Biosystem, Menarini, Florence, Italy). EBER sequence was detected by 
anti-fluorescin antibody associated with a sensitive 'Bond polymer 
Refine' chromogenic detection system in an automated immunostainer 
(Bondmax, Vision-Biosystem, Menarini, Florence, Italy). 
 
3.9 Karyotyping  
  
Cytogenetic analysis was performed with standard methods on both 
cells cultured in vitro and cell suspensions from tumors developing 
after in vivo injection of VR09 cell line: 10- 20x10
6 
cells were 
centrifuged, resuspended in RPMI 1640 medium containing 20% fetal 
bovine serum (FBS, Lonza, Verviers, Belgium) and cultured for 24 
hours. Before harvest, 0.15 µg/ml colchicin (Eur-Clone, Italy) was 
added. Chromosome preparation and staining using QFQ technique was 
performed according to standard protocols. Karyotypes were scored 
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according to the International System for Human Cytogenetic 
Nomenclature (ISCN) (Brothman, 2009). Images were captured with a 
ZEISS Axioplan microscope (ZEISS, Jena, Germany) and evaluated by 
Cytovision applied imaging system (Molecular Devices, New Milton).  
 
3.10 Fluorescence in situ hybridization (FISH) 
 
Interphase cytogenetic FISH was performed on nuclei from VR09 cell 
suspension and formalin-fixed and paraffin-embedded tissue sections 
from in vivo tumor masses developing after in vivo injection of VR09 
cell line. The following kits were used: LSI BCL-2 dual color probes 
for 14q32;18q21 (Abbott-Vysis, Olympus), LSI CCND1 (11q13) 
break-apart probes (Abbott-Vysis, Olympus), LSI IGH/CCND1 probe 
for 11q13-14q32.3 (Abbott-Vysis, Olympus), LSI MYC dual color 
break-apart probe for 8q24 (Abbott-Vysis, Olympus), LSI C-MYC dual 
color probes for 8q24-14q32 (Abbott-Vysis, Olympus) and CEP 
(centromeric) mapping 12p11.1-q11.1 (Abbott-Vysis, Olympus). 
Chromosome 9 probes from human painting box kit (Spectral Imaging) 
were also used to identify whole chromosome 9 on metaphases of cell 
derived from in vivo tumor masses. The procedure was performed 
according to the methods described elsewhere (Brunelli, 2008).  
FISH slides were examined by using either Axioplan (Zeiss, Germany) 
or Olympus BX61 (Olympus, Hamburg, Germany) epifluorescent 
automated microscopes. The signals were recorded using a CCD 
camera (Axiocam HRm, Zeiss and Digital Camera Olympus), and score 
was assigned according to manufacturer‟s instructions, available in 
each commercial FISH kit. 
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CHAPTER 4 
 
4 RESULTS 
4.1 Establishment and characterization of VR09 cell line 
 
Primary cells proliferated very slowly during the first six weeks of 
culture, with a consequent decline in cell number. Remaining cells 
formed a few clusters of proliferation and started growing in suspension 
forming small round clumps (Figure 3A). At ten weeks of culture a 
stable proliferating cell line (designed VR09) was established, with a 
doubling time of approximately 84 hours. May-Grünwald-Giemsa 
staining showed a wide cellular size spectrum, from medium to large 
cells, with predominantly plasmacytoid features and occasional bizarre 
shapes: cells had a round-ovoid, often eccentric or moderately irregular 
nucleus, with compact chromatin and abundant basophilic cytoplasm. 
(Figure 3B).  
At present, VR09 cells grow in suspension in RPMI 1640 medium 
supplemented with 10% heat-inactivated FBS without requiring any 
other supplements, and can be vitally stored in a medium consisting of 
60% RPMI 1640 medium, 30% heat-inactivated FBS and 10% DMSO. 
Once thawed and put in culture, VR09 cell line grows rapidly and 
maintains the same doubling time of the early culture. Cells are 
optimally maintained at 500,000 and 1,000,000/mL cell density and 
may be split 1:5 every 72 hours.  
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Figure 3. VR09 cell growth in suspension and morphological features, as assessed  by 
May-Grünwald-Giemsa staining. A. Small and round clumps in suspension. B. 
Plasmacytoid appearance, with irregular nucleus, compact chromatin and abundant 
basophilic cytoplasm.  
 
4.2 Immunophenotyping and immunohistochemistry 
 
Immunophenotyping by flow cytometry was performed on VR09 cell 
line at 10 weeks and one year after continuous culture, resembling the 
phenotype of atypical B-cell chronic lymphoproliferative disease with 
plasmacytic features found in the patient. In particular, cells were 
CD45
+
, CD19
+
, CD20
+
, CD22
+
, CD23
+
, CD43
+
, CD38
+
, CD138
+/-
, 
IgD
+
, IgM
+
, IgG
+
 and kappa chains
+
, and negative for CD3, CD5, 
CD10, CD25, CD79b, CD103, FMC7 and lambda chains (Figure 4); 
Zap-70, as expected, was not expressed.  
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Figure 4. Immunophenotyping of VR09 cell line (grey and filled curves) and cell 
suspensions from in vivo tumor mass (black and filled curves), as compared with 
isotype control (white curves).  
 
VR09 surface markers remained unchanged over time, with the 
exception of CD20, whose expression had a 1 log increase as compared 
to starting culture.  
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Results of immunohistochemistry performed on FFPE cell block are 
summarized in Table 4: all the markers shown by flow cytometry was 
confirmed, with the exception of IgG and CD38 expression that 
resulted negative by immunohistochemistry; proliferation index (Ki-
67+ cells) was about 40%. In addition, cells were positive for Bcl-2, 
MNDA (Kanellis, 2009)
 
and MUM1, and negative for Bcl-6, Cyclin 
D1, Annexin A1, DBA44, FOXP1, GCET1, ZAP-70, TdT and TRAP; 
other markers, such as PAX-5, Sox11 and TCL1, were weakly and 
variably expressed. In summary, neoplastic cells displayed a late B-cell 
phenotype (MNDA+, FOXP1+, IRF4/MUM1+, cyK+, CD138+/-), 
while germinal center markers (Bcl-6, CD10, TCL1, GCET1) and 
immature B-cell markers (TdT) were negative. Cyclin D1 was included 
to exclude the remote possibility of a blastoid variant of mantle cell 
lymphoma, and also because plasma cell myeloma can be cyclin D1-
positive. Hairy cell leukemia markers (Annexin A1, DBA44, TRAP) 
were investigated to exclude the very remote possibility of evolution 
from hairy cell leukemia (in consideration of the clinical history). 
 
4.3 Cell cycle 
 
DNA content of VR09 cell line was analyzed at six months and one 
year of culture. High S-phase rate was observed (diploid S 22.66 %), in 
absence of tetraploid or aneuploid peak, as compared to the control 
(diploid S: 1.64%).  
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4.4 IGVH, TP53, CARD11 and CD79B mutation analysis 
 
VR09 cell line showed VH3-7/D4-23/JH4 gene rearrangement. The 
comparison of the sequence with published germline sequences showed 
95% identity, with evidence of somatic hypermutation (SHM) in the 
VH region, defined as more than 2% mutations as compared to 
germline sequences. The analysis of the sequences obtained from both 
strands of cDNA and compared with the published TP53 sequence 
(U94788.1) showed that this sequence in VR09 cell line was wild-type. 
CARD11 sequence was compared to the published one (NM_032415): 
VR09 cell line showed a silent heterozygous mutation leading to 
D533D variation in the protein linker region. Finally, VR09 cell line 
expressed all the three isoforms of the CD79B gene (NM_000626.2; 
NM_021602.2; NM_001039933.1): cDNA sequence analysis showed 
that variants 1 and 3 had an homozygous silent mutation in exon 3 
leading to C122C variation in the Ig-like V-type protein domain, 
involving the disulfide bond; moreover, variant 2 had an Alanine 
insertion in the exon 2b corresponding to the protein signal peptide 
region. 
 
4.5 Mouse Model 
 
All six mice injected s.c. with VR09 cell line developed spherical tumor 
mass around the site of injection by 34-74 days after treatment and 
were sacrificed 10 days later. Subcutaneous mass and tumor incidence 
in vivo are shown in Figure 5.  
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Figure 5. A. Spherical subcutaneous mass (arrow) in Rag-2
−/− γ-chain-/- mice 36 
days after VR09 cell line injection (representative case). B. Timing of tumor 
development in vivo (6 mice s.c. injected with 5x10
6
 cells/mouse). 
 
Cells from subcutaneous masses were evaluated by H&E and Giemsa 
staining: cells ranged from medium to large size, with irregular nuclei, 
condensed chromatin without nucleoli and basophilic cytoplasm. 
Immunohistochemistry showed no significant differences in tumor cell 
immunophenotype as compared to VR09 cell line in culture (Table 4 
and Figure 6).  
 41 
 
Figure 6. High magnification (20X) of histological sections of tumors developing after in 
vivo injection of VR09 cell line. Lymphoid infiltrates display large size, plasmablastic-
plasmacytic features and high Ki-67 index. Cells express CD19, CD20, CD138, CD79a, 
IgM, IgG and EBV protein (EBER). 
Cells suspensions obtained by disaggregation of in vivo tumor masses 
showed proliferative capacity when cultured with the same procedure 
used for primary VR09 cell line. Again, cells appeared as small and 
round clumps with plasmacytoid features and bizarre shape: 
immunophenotyping on these cells after two months of continuous 
secondary culture did not show any significant change of cell surface 
marker expression as compared to primary VR09 cell line (Figure 4). 
Of the six i.v injected mice, three were euthanized after 30 days from 
injection and the other 3 after four months: histopathologic examination 
of spleen, liver, femurs, lymph nodes and lungs did not show any 
evidence of tumor infiltration. In addition, no circulating human 
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CD45/CD19-positive cells were detected in peripheral blood of both 
s.c. and i.v. injected mice.  
 
4.6 EBV status 
 
EBV RNA evaluation was performed on FFPE cell blocks and tumoral 
masses by using a fluorescein-conjugated probe coupled to 
chromogenic detection (Bond ISH EBER Probe, Vision-Biosystem, 
Menarini, Florence, Italy). In situ hybridization for EBV-encoded RNA 
(EBER) showed a clear nuclear signal in both VR09 cell line and 
tumors (Table 4 and Figure 6). 
 
4.7 Karyotyping 
 
Chromosome analysis performed at 10 weeks and one year of 
continuous culture showed a male karyotype with 47 chromosomes. All 
metaphases exhibited trisomy of chromosome 12. Karyotype was 
repeated on secondary cell cultures obtained by disaggregation of in 
vivo tumor masses, thus revealing the presence of additional structural 
chromosome aberration involving chromosomes 7 and 9, i.e. 47, XY, 
der(7)(9qter->9p23::7p13->7qter), +der(7)(9qter->9p23::7p13->7qter), 
-9, +12 (Figure 7A). 
 
4.8 Fluorescence in situ hybridization (FISH) 
  
Adjacent or fused fluorescent signals (LSI BCL-2) were found in 5% of 
nuclei on tissue sections; this percentage is below the established 10% 
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signal threshold for considering a case positive (adjacent signals are 
generated by random ovelapping of genomic regions). No break-apart 
fluorescent signals were found for LSI CCND1 (11q13) and LSI MYC 
(8q) probes on tissue sections. No adjacent or fused fluorescent signals 
were found for LSI IGH/CCND and LSI C-MYC dual color probes 
(4% of nuclei, below threshold). Trisomy of chromosome 12 was found 
in 45% of nuclei. The rearrangement involving chromosomes 9 and 7 
detected by karyotyping on cell suspension from in vivo tumor mass 
was confirmed by fluorescent signals derived from hybridization of 
chromosome 9 DNA probes to target chromosome 9 (chromosome 9 
paint) (Figure 7B). 
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 Figure 7. Karyotyping (A) and chromosome 9 painting by FISH (B). 
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5 DISCUSSION 
 
Several lymphoma cell lines have been obtained so far, but cell lines of 
DLBCL with plasmacytic differentiation are still lacking. We have 
established and characterized of novel human EBV-positive DLBCL 
cell line with plasmacytic differentiation (VR09) obtained from a 
patient with atypical B-cell chronic lymphoproliferative disease with 
plasmacytic features.  
VR09 cell line consists of cells with medium-large size and plasmacytic 
(rarely plasmablastic) features. Such a morphologic pattern may 
wrongly induce to consider VR09 as a variant of plasmablastic 
lymphoma that is, indeed, characterized by plasmablastic cells mixed 
with a variable number of mature plasma cells. However, VR09 
phenotype does not correspond to plasmablastic lymphoma, due to 
strong expression of B cell markers CD20 and CD79 that are usually 
absent in the latter (Taddesse-Heath, 2010). Besides expressing other 
pan-B markers, such as CD19 and CD22, VR09 displays high degree of 
Ki-67 proliferation marker and the immunohistochemical pattern of 
activated DLBCL, i.e. the expression of MUM1 and the negativity for 
GCET1, CD10, BCL-6 markers (Choi, 2009). Moreover, the positivity 
of MUM1, the expression of immunoglobulins, and the partial 
expression of CD38 and CD138 suggest the status of terminal B cell 
differentiation. Consequently, VR09 may be considered a DLBCL 
variant corresponding to the intermediate step between activated B cells 
and plasmablasts, i.e. a late activated stage of B cell maturation, not 
entirely completed (Jourdan, 2009). 
Some evidence suggests that DLBCL with plasmablastic and 
plasmacytic differentiation represents a clinically and pathologically 
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heterogeneous spectrum of entities, whose diagnosis may often 
represents a particular challenge (Teruya-Feldstein, 2005). Only one 
study reported cases of DLBCL showing a phenotype similar to VR09 
cell line, i.e. CD20+, MUM-1+, CD138+/-, BCL-6-, IgM+. The 
Authors explained this entity as a result of transformation of transient B 
cell populations characterized by plasmablastic morphology and 
increasing plasmacytic features, and associated to the loss of GC and 
acquisition of post-GC immunophenotypic features (Simonitsch-Klupp, 
2004). VR09 cell line may be close to this entity, although the VR09 
morphology resembles activated B cells with plasmacytic features 
rather than plasmablastic cells. Thus, VR09 would represent an earlier 
stage in the continuum spectrum of neoplastic differentiation that 
ranges from conventional activated DLBCL to plasma cell disorders 
(Montes-Moreno, 2010). 
All the markers shown by flow cytometry was confirmed by 
immunohistochemistry, with the exception of CD38 that resulted 
negative by immunohistochemistry. However, the latter is less sensitive 
than immunophenotyping. Furthermore, tissue sections of tumor masses 
obtained from VR09 resulted positive for CD38 also by 
immunohistochemistry.  
When compared to the cell population collected from the patient, VR09 
cells showed larger size, but also plasmacytoid features and all the 
markers of the peripheral blood B cells, i.e CD19, CD20, CD22, 
CD138, surface immunoglobulins at high level, and clonal restriction 
for k surface light chain, while confirming its negativity for CD5 and 
CD10 markers. Morphology and immunophenotype of patient‟s 
peripheral blood cells were in agreement with B-cell chronic 
lymphoproliferative disease with plasmacytic features, without peculiar 
patterns that suggested alternative diagnosis. Low-grade B-cell 
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lymphoproliferative disorders, such as CLL/small lymphocytic 
lymphoma and marginal zone B-cell lymphoma, sometimes may have 
overlapping features, thus hampering differential diagnosis (Rozman, 
1995; Pangalis, 1999). Furthermore, many types of small B cell 
lymphoid neoplasms can display plasmacytic differentiation and 
phenotype resembling lymphoplasmacytic lymphoma (Campo, 2011; 
Hjalmar 1998). Lymphoplasmacytic lymphoma consists of small 
lymphocytes, plasmacytoid lymphocytes and plasma cells, and express 
IgM and pan-B-cell antigens, such as CD19, CD20 and CD22. 
Moreover, it is usually negative for CD5, CD10 and variably to CD23 
(Lin P, 2003). Although this phenotype is similar to the cells from 
which VR09 derived, we concluded for atypical B-chronic 
lymphoproliferative disease with plasmacytic differentiation rather than 
plasmacytic lymphoma, due to the lack of IgM paraprotein.  
Other chronic lymphoproliferative diseases may undergo 
transformation into DLBCL, although it occurs more frequently in CLL 
(Rossi, 2009). Thus, we think that VR09 cell line is the result of in vitro 
transformation of the original atypical chronic lymphoproliferative 
disease due to the presence of latent EBV infection in the primary cells 
(Nilsson, 1992). The association between EBV infection and indolent 
B-cell lymphoma has been reported (Jeffrey, 2010; Varghese, 2008); 
some cases of EBV-positive DLBCL developed from chronic 
lymphoproliferative diseases, and it is well known that EBV may have 
a potential role in the progression of the indolent disease (Tsimberidou 
2005; Lin 2003). Thus, the positivity of EBV in VR09 cell line is not 
surprising.  
We found the presence of chromosome 12 trisomy in VR09. This 
aberration is often detected in CLL (Stilgenbauer,
 
1998) and in other 
chronic B cell malignancies, including sometimes lymphoplasmacytic 
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lymphoma (Hjalmar, 1998). Moreover, it has been reported that 
chromosomal aberrations usually found in indolent lymphoma are 
detectable also in related DLBCL (Ghesquires, 2006). These features 
confirm that VR09 cell line originated from a low grade 
lymphoproliferative disease. The additional chromosomal abnormalities 
found in VR09 cell line after secondary culture is not surprising, as cell 
lines are usually genetically unstable and may acquire numerical and 
structural chromosomal alterations (Drexler, 2002). 
Interestingly, VR09 cell line grows subcutaneously without either 
dissemination in peripheral blood or engraftment when administrated 
i.v. This strange peculiarity could be simply due to the in vivo model 
used. Rag2
-/- γ-chain-/- is a strain of immunodeficient mice with 
C57B16/10 background devoid of functional B and T cells because of 
the complete lack of function of the V(D)J recombinase enzyme 
system, and displaying deficient innate immunity due to the absence of 
γ-chain of interleukin-2-receptor (Shinkai, 1992). This model has the 
advantage to show a stable phenotype without developing spontaneous 
tumors, as compared to SCID mice (Van Rijn, 2007). Indeed, the 
injection of VR09 cell line into mice led to 100% incidence of 
developing tumors in vivo, always maintaining the same features. 
Another important finding is the detection in VR09 cells of a 
synonymous CD79B variant involving the insertion of Alanine in the 
exon 2b of variant 2. This variant may be physiological, as it has been 
detected in other isoforms; however, it has never been described before 
in variant 2. A recent study suggested that also synonymous variants 
may be involved in the pathogenesis of some diseases (Brest, 2011). 
Somatic mutations affecting the immunoreceptor tyrosine-based 
activation motif (ITAM) of CD79B signalling sequence have been 
detected in ABC DLBCLs, but rarely in other lymphomas; this 
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evidence further supports the activate pattern of VR09 (Davis 2010). As 
the constitutive activation of the NF-kB pathway, due to abnormalities 
in a variety of upstream proteins including Card-11, is a characteristic 
feature of ABC DLBCL (Lenz, 2008), we studied this protein. VR09 
cell line did not display the common missense mutations of Card11; 
however, the detection of synonymous mutations of the protein 
confirms the accuracy of sequencing method. 
In conclusion, VR09 is a new cell line of activated DLBCL with 
plasmacytic differentiation that grows as solitary tumor once injected 
s.c. in immunodeficient mice. This model could be useful for further 
studies about the development of DLBCL in patients with low-grade B-
cell lymphoproliferative disorders with plasmacytic differentiation, 
which represents a rare but possible event in clinical practice. 
Furthermore, it may represent a model for the development of target 
therapies in ABC lymphomas. 
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